Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma

Mamta Parikh, Matthew E. Tenold, Lihong Qi, Frances Lara, Daniel Robles, Frederick J Meyers, Primo N. Lara

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Although immune checkpoint inhibitor-based therapy has improved the outcomes of many patients with metastatic renal cell carcinoma (mRCC), most eventually develop disease progression. Newer agents that modulate immune response can possibly potentiate checkpoint inhibitor therapy. The ITK/ETK/BTK inhibitor ibrutinib has been reported to inhibit myeloid derived suppressor cells in preclinical models and to potentiate immunotherapy. We conducted an investigator-initiated trial of ibrutinib plus the PD1 inhibitor nivolumab in mRCC patients, particularly in those previously exposed to immune checkpoint inhibitors. METHODS: Eligible patients had mRCC of any histologic subtype, completed at least one line of prior systemic therapy which could have included prior immunotherapy, and had acceptable end-organ function with ECOG performance status of 0-2. Treatment consisted of nivolumab 240mg intravenously every 2 weeks plus ibrutinib 560mg (dose level 0) or 420mg (dose level-1) orally once daily. Cycle length was 28 days. Dose limiting toxicity (DLT) was defined as any Grade 3 or higher adverse event (AE) attributable to therapy. After identification of the recommended phase 2 dose (RP2D), up to 19 patients were enrolled to an expansion cohort to further evaluate toxicities and any early evidence of efficacy. The primary endpoints of the trial were establishment of RP2D and progression-free survival (PFS). RESULTS: A total of 31 patients were enrolled, 6 to dose level 0, 7 (of which one was not evaluable for DLT) in dose level-1, and 18 in the expansion cohort. Median age was 60 years (range, 36-90), most had clear cell histology (n=27; 87%), and most had prior immune checkpoint inhibitor therapy (n=28; 90%). Three patients experienced one DLT each, all in dose level 0 (all Grade 3), namely elevated lipase, hypoalbuminemia, and nausea. No DLTs were seen in dose level-1 which was declared the RP2D. The most common Grade 3 or higher AEs include anemia (n=5), lymphocyte count decrease (4), nausea (2), and hypotension (2). Of 28 patients evaluable for response, one patient (3.6%) had a complete response, 2 (7.1%) had a partial response, and 11 (39.2%) had stable disease, for an objective response rate of 10.7%(95%CI: 3.7%-27.2%) and a disease control rate of 50%(95%CI: 32.6%-67.4%). All responders had received prior immune checkpoint inhibitor therapy. Median PFS was 2.5 months (95%CI, 1.9-4.8) while median OS was 9.1 months (95%CI, 6.6-19.0). CONCLUSIONS: Ibrutinib at a dose of 420mg orally once daily in combination with nivolumab 240mg IV every 2 weeks is feasible and tolerable in mRCC patients. No unique immune-related AEs were observed. Anti-tumor activity was seen in patients previously exposed to PD-1 targeted therapy.

Original languageEnglish (US)
Pages (from-to)181-187
Number of pages7
JournalKidney Cancer
Volume5
Issue number4
DOIs
StatePublished - 2021

ASJC Scopus subject areas

  • Nephrology
  • Oncology

Fingerprint

Dive into the research topics of 'Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this